This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Stryker Flexes Its Medtech Muscles

NEW YORK (TheStreet) -- It wasn't that long ago when the major concern about Stryker (SYK - Get Report) was whether the company had enough legal expertise to navigate issues related to the company's artificial hip implants. They were considered faulty and had made it to the recall list.

As a consequence, the Street turned sour on Stryker's stock. And these shares began trading at a noticeable discount to fair value. Investors questioned whether the stock was worth the trouble. After a recent change in management, growth is starting to pick up in areas like joint reconstruction. With shares now at 52-week highs on strong margin improvements, I can't say Stryker is a bargain today. It's hard nonetheless to bet against a company with momentum now firmly on its side.

With fourth-quarter revenue climbing more than 5% year over year, Stryker ended the 2013 campaign on a strong note. Although growth has returned to the entire industry, on an organic basis, Stryker's 6% results stood out pretty firmly from other well-run medtech companies like Medtronic (MDT) and Covidien (COV).

Growth was led by the Reconstructive business, which advanced 8% year over year. There were concerns that the company had begun to cede market share to Johnson & Johnson (JNJ) due to product recalls. But management found ways to grow 8% in that all-important hip category. This is while revenue in knees grew almost 5%.

It's true that the company didn't outperform Johnson & Johnson, which grew knees by 8%. But Johnson & Johnson has not had these sorts of deficits to work with. Nor should investors have expected Stryker to post numbers anywhere near what the company actually produced. Investors shouldn't dismiss the solid 12% growth in the trauma and extremities segment, either.

Medical instruments posted more than 7% growth. As much as I've followed Stryker over the past several quarters, I have to say that this was by far an unexpected occurrence. On a relative basis, the company had not shown any signs of strength in instruments for some time. And there were concerns that, among others, Covidien (which had begun to apply pricing pressure) was beginning to steal market share. But there was no evidence of that in the earnings report.

Without further evidence, I'm not ready to say that Stryker is suddenly dominating the markets in instruments. But the results I've seen from Covidien and Johnson & Johnson do support the notion that there has been a broad recovery within the entire industry.

Last but not least, investors have to be encouraged by the 7% growth in the medical and surgical products division. This is an area that has long been considered the weak link among all of Stryker's businesses. And even with the relatively weak 5% growth in neurotechnology, the company more than made up for this by doubling the output in spine, which produced 10% growth.

In that regard, with each of the segments performing so well, the challenge now is for Stryker's management to figure out ways to differentiate the company's offerings from those of, say, Abbott Labs (ABT). And I don't believe it makes sense at this point to nitpick about underperforming areas, especially when there were concerns that endoscopy and medical devices would be stagnant. And it's also worth noting that even with the soft growth in neurotechnology, Stryker still outgrew Covidien. It's not farfetched to say that the company has stolen market share.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
SYK $109.94 0.00%
AAPL $93.64 0.00%
FB $118.57 0.00%
GOOG $698.21 0.00%
TSLA $241.80 0.00%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs